IQVIA (NYSE:IQV) Price Target Lowered to $265.00 at Deutsche Bank Aktiengesellschaft

IQVIA (NYSE:IQV) had its price target reduced by Deutsche Bank Aktiengesellschaft from $270.00 to $265.00 in a research note released on Friday, Benzinga reports. They currently have a buy rating on the medical research company’s stock.

A number of other brokerages have also recently commented on IQV. Evercore ISI lowered their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. JPMorgan Chase & Co. lowered their price target on IQVIA from $288.00 to $279.00 and set an “overweight” rating for the company in a research report on Wednesday, October 23rd. Argus upgraded IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Barclays reduced their price objective on IQVIA from $275.00 to $260.00 and set an “overweight” rating for the company in a research note on Tuesday, October 15th. Finally, The Goldman Sachs Group reduced their price objective on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $261.24.

IQVIA Stock Performance

IQV traded up $3.34 on Friday, reaching $209.16. 1,791,887 shares of the stock were exchanged, compared to its average volume of 1,125,496. The company’s 50-day moving average price is $234.31 and its 200 day moving average price is $229.74. IQVIA has a fifty-two week low of $181.03 and a fifty-two week high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.85. The firm has a market capitalization of $38.13 billion, a PE ratio of 27.45, a PEG ratio of 2.01 and a beta of 1.51.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On IQVIA

A number of hedge funds have recently made changes to their positions in the company. Canada Pension Plan Investment Board raised its holdings in shares of IQVIA by 6.6% during the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after acquiring an additional 211,653 shares during the last quarter. Lazard Asset Management LLC grew its position in shares of IQVIA by 0.9% in the first quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock valued at $825,416,000 after purchasing an additional 30,014 shares in the last quarter. Farallon Capital Management LLC grew its position in shares of IQVIA by 3.1% in the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after purchasing an additional 86,870 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of IQVIA by 3.8% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company’s stock worth $634,927,000 after buying an additional 92,293 shares during the period. Finally, Capital Research Global Investors raised its stake in shares of IQVIA by 7.2% in the first quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock valued at $540,882,000 after acquiring an additional 143,533 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.